Latent Tuberculosis in Children: Diagnosis and Management
|
|
- Amberlynn Ford
- 7 years ago
- Views:
Transcription
1 Indian J Pediatr (April 2011) 78(4): DOI /s SYMPOSIUM ON PEDIATRIC TUBERCULOSIS Latent Tuberculosis in Children: Diagnosis and Management Meenu Singh & Arushi Gahlot Saini & Nidhi Anil & Amit Aggarwal Received: 26 August 2010 / Accepted: 1 November 2010 / Published online: 3 December 2010 # Dr. K C Chaudhuri Foundation 2010 Abstract Control of tuberculosis in children often escapes attention because of the paucibacillary nature of the illness. However, they contribute much of the morbidity, mortality and future reservoir of the disease which reiterates the importance of risk-factor based screening for latent infection and appropriate treatment. We review the modalities and importance of diagnosis and treatment of latent tuberculosis infection in children. At this time, the role for interferon-gamma release assays in low-income, highburden settings is rather limited but further research in the coming years might clear their role in children. An important emerging area of research is the development of an improved skin test for TB that uses specific mycobacterial antigens rather than tuberculin, thus is more feasible and useful in resource limited settings. Keywords Latent tuberculosis. Children. Diagnosis. Treatment. Interferon-gamma Introduction Latency has been defined by Anderson [1] as the presence of any tuberculous lesion which fails to produce symptoms of its presence. Latent tuberculosis infection (LTBI) is defined as a positive tuberculin skin test (TST) in a child who has no signs and symptoms of pulmonary or extra pulmonary TB disease and has a chest radiograph that is either not suggestive or has evidence of healed TB disease M. Singh : A. G. Saini (*) : N. Anil : A. Aggarwal Department of Pediatrics, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India doc.arushi@gmail.com (e.g. granuloma, calcification) [2]. Such persons are not infectious in contrast to active tuberculosis cases who are infectious as well as symptomatic [3]. Among children in developing countries, tuberculosis contributes to 2 5% of annual risk of infection and 8 20% of deaths, the infection being acquired primarily from the adults in their surroundings. The estimated life time risk of developing active disease for a child infected with Mycobacterium tuberculosis as indicated by positive TST is about 10 20%, out of which 5% are likely to develop disease in the first year after infection and another 5% in the rest of their lifetime [4]. Approximately 40% of infected infants, if left untreated, develop radiologically significant lesions compared with 24% between 1 and 10 years and 16% in years of age [5]. Marais et al. [6] have shown the effect of age of the child at acquisition of infection on the occurrence of TB disease (Table 1). LTB Diagnosis As patients with LTBI are by definition healthy and do not present with radiological abnormalities, screening must rely on immunological markers of infection. An overview of the available diagnostic modalities is presented with shifting focus from the century old TST to the more accurate T-cell interferon gamma release assays (IGRAs) [7 9]. The major differences amongst the IGRAs and TST are presented below in Table 2. Tuberculin Skin Test First described by Robert Koch in 1890, the Mantoux test (Tuberculin sensitivity test, Pirquet test, or PPD test for Purified Protein Derivative) is named after Charles Mantoux,
2 Indian J Pediatr (April 2011) 78(4): Table 1 Risk of progression from tuberculosis (TB) infection to disease Age at primary infection (yr) No disease (%) Pulmonary disease (%) < to to to <0.5 > <0.5 Miliary or central nervous system TB (%) a French physician who created his test in Tuberculin is a glycerol extract of the bacillus while PPD introduced in 1934 is its standardized version. In 1939, PPD-S was produced by Seibert and Glenn which remains the international standard. A standard dose of 5 tuberculin units (0.1 ml) is injected intradermally (except in UK where 2TU of SSI {Staten Serum Institute} tuberculin RT23 in 0.1 ml solution is used). A person exposed to the bacteria should mount an immune response in the skin containing the bacterial proteins which is read h later by measuring the diameter of induration across the forearm in millimeters and gauged against standard cutoffs [10]. Due to its low specificity, falsepositives are caused by non-tuberculous mycobacteria or previous administration of BCG vaccine [11]. Conversely, immunologically compromised children, such as with HIV and low CD4 counts or severely malnourished fail to mount an immune response, thus falsely negative. Paradoxically, the TST has more false negative results in populations with higher risk of TB reactivation; 10% of children with confirmed TB do not react to the TST at the time of diagnosis. A new generation of LTBI diagnostics, the IGRAs seem to be significantly more accurate than the skin test [12] and three of them have been approved for clinical use by Food and Drug Administration (FDA). Quantiferon-TB Gold (QFT-G) Approved by FDA in 2005, QFT-G is an enzyme-linked immunosorbent assay (ELISA) based whole blood test in which blood samples are incubated with the mycobacterial antigens (ESAT-6 and CFP-10) for 16 to 24 h. If the patient is infected with M. tuberculosis, their white blood cells will release interferon-gamma in response to contact with the TB antigens which is quantified. Quantiferon-TB Gold In-Tube Test (QFT-IT) Approved by FDA in Oct 2007, this ELISA-based assay for quantification of interferon-gamma uses heparinized whole blood sample drawn directly into specialized three blood collection tubes with antigens (ESAT-6, CFP-10, and TB7.7 proteins) dried onto their walls and transferred to an incubator within 16 h of collection. It is marketed to have specificity of >99% in low risk individuals and sensitivity of 92% in individuals with active disease [10]. Regarding its utility in children, a study by Lighter et al. [13] reveals that QFT-IT is a specific test for M. tuberculosis exposure in children, with performance characteristics similar to those for adults residing in regions with low levels of endemic disease though sensitivity for children <2 years of age needs further evaluation. T-SPOT.TB It is a type of enzyme-linked immunospot (ELISPOT) assay in the whole blood to count the number of effecter T cells i.e. white blood cells that produce interferongamma. This gives an overall measurement of the antigen load on the immune system, which can reveal the presence of subclinical disease faster (within 24 h) and accurately. Studies describe a sensitivity of 85% for ELISPOT vs 70% for TST in children with confirmed or Table 2 Main differences between tuberculin skin test (TST) and T-cell interferon-gamma release assays (QFT-G and T-SPOT.TB) [16] TST QFT-G T-SPOT.TB Influence by prior BCG vaccination Yes No No Influence by non-tb mycobacteria Yes No No Booster effect if repeated Possible No No False positives Possible No evidence No evidence False negatives Possible Possible Possible Correlation with exposure intensity Partial Yes Yes Antigens used PPD RT23 ESAT-6, CFP-10 ESAT-6, CFP-10 Technique In-vivo skin test ELISA ELISPOT Results reported in mm of induration IFN-gamma units Spot-forming units Adverse reactions Rare None None Patient visits to complete testing Two One One Laboratory infrastructure required No Yes Yes
3 466 Indian J Pediatr (April 2011) 78(4): highly probable TB [14] and sensitivity up to 93% for established culture proven cases [15]. Individual observations hint that the IGRAs convert to positive before the TST [17] and are significantly more specific than the latter [12]. Recent longitudinal studies indicate higher positive predictive values for development of future TB with IGRAs compared to TST [18, 19]. While Connell et al. [7] described a high rate of indeterminate test results among children exposed to TB but not among children with documented TB, Nakaoka et al. [20] reported better correlation of the blood tests with intensity of exposure than the TST. The reason for these discrepancies is unclear but perhaps is related to the tuberculin used, the cutoff considered for positivity or the background prevalence rate of non-tb mycobacteria infection. Detjen et al. [15] have shown that the blood tests allow a distinction between infection with mycobacterium tuberculosis and with nontuberculosis mycobacteria in children in a low prevalence country. Though ELISPOT assay has been reported to correlate more closely with M. tuberculosis exposure and to be unaffected by BCG vaccination [21], it proved slightly less sensitive than the TST in its diagnosis of infection from recent exposure in Gambian children with no confounding effect of prior BCG vaccination on either tests. It was also suggested to combine the two tests for maximal sensitivity in recently exposed cases [22, 23]. Nicol et al. [24] observed that the sensitivity of T-SPOT.TB was no better than that of the TST for culture confirmed tuberculosis (50% and 80% respectively), poorer for the combined group of culture-confirmed and clinically probable tuberculosis (40% and 52% respectively) and the specificity of both the tests was 84% for children clinically categorized as not having TB. The most important findings of this study were that negative T-SPOT.TB results could not be used to exclude active TB in young children at risk because children <12 months of age were more likely to have positive T-SPOT.TB results while TST remained unaffected by age. Thus, though IGRAs have high specificity, correlate better than TST with the intensity of contact with the infectious case in children [20] and can be repeated without any booster effect, yet they do not differentiate between LTBI and active disease just like TST and hence their use for the diagnosis of tuberculosis remains controversial [8, 25, 26]. The possible influence of a TST performed before blood sampling for IGRAs has been shown by some [27] while refuted by others [17]. Among the IGRAs, QuantiFERON-TB tests were more likely than T-SPOT. TB to give indeterminate results in children <4 years of age as per one study [28]. As a new specific skin test, Arend et al. [29] compared rdesat-6 skin test to TST in adults in a double blind randomized phase 1 study and found it safe as well as feasible though it s utility in children, sensitization after repeated doses and role of additional CFP-10 on sensitivity needs evaluation. Why Children Need Treatment Treatment is recommended for the following reasons [30] in all children and adolescents diagnosed with LTBI- 1. Infants and children less than 5 years of age are more likely to be infected recently, so the risk for progression to TB disease is high, 2. Risk for severe disease, including meningitis and military forms, is inversely related to the age of the child at acquisition of the disease, 3. Children with LTBI have more years at risk for the development of disease later in life, 4. Children with LTBI become adults who act as reservoirs, 5. The drugs used for treatment are relatively safe in the pediatric population Thus, screening children in contact with TB cases is in the best interest of the child for personal health and public health at large for disease control. Terminology CDC [31] recommends the use of terminology Treatment of Latent Tuberculosis Infection rather than Preventive Therapy and Chemoprophylaxis used previously as the latter rarely result in true primary prevention (i.e. prevention of infection in persons exposed to an infectious case) rather means prevention of development of active TB disease in persons currently well but infected with M. tuberculosis. Treatment Regimens Currently in Use It is imperative to rule out active TB before treatment for LTBI is begun. To treat latent TB in a child with active disease is a serious error with grave risk of inadequate treatment and emergence of drug-resistant strains. Based on the results from the clinical trials [32 34], the currently recommended treatment regimen in developed countries is 9 months of Isoniazid (INH) monotherapy with a protection efficacy of 70 90%. Daily Rifampicin is used for the same when INH is not tolerated or the child was exposed to an INH-resistant, Rifampicin-susceptible source case [10]. Children generally tolerate INH better than adults with
4 Indian J Pediatr (April 2011) 78(4): minimal risk for drug-related hepatitis [35, 36]. The duration of 9 months is recommended because the maximal beneficial effect of INH is likely achieved by this time and minimal additional benefit is gained by extending the therapy to 12 months [33]. Also, routine administration of pyridoxine is not advised unless there are (a) breastfeeding infants (b) children with diets likely to be deficient in pyridoxine (c) children experiencing paresthesias while taking INH. Because of high prevalence of INH resistance, Finnell et al. [37] suggest the use of Rifampicin for 6 months for children originating from countries with >11% INH resistance. As per their study, the risk of TB reactivation was maximum with 9 months of INH and minimum with 6 months of Rifampicin, whereas combination of INH and Rifampicin is the most effective. Safety and acceptability of Rifampicin therapy (10 mg/kg/day for 6 months) in adolescents has been found satisfactory by Villarino et al. previously [38]. In fact, Ormerod et al. [39] in their observational study over 15 years period suggested that 3 4 month regimens of Rifampicin plus INH (10 mg/kg/ day each) were effective in the treatment of LTBI in children and adolescents 15 years of age. The mild increase in serum liver enzymes seen in many children with these drugs is generally clinically silent [36, 40]. Combined treatment approach with INH and Rifampicin is used assuming an increased likelihood of the pathogen being susceptible to at least one of the two drugs. A 3 months regimen of the aforesaid combination has been used in UK [41] with programmatic data showing both longer and shorter regimens to be equally efficacious [39, 42]. However, Finnell [37] found this regimen least costly but 0.7% less efficacious than rifampin for 6 months (in areas with INH resistance <80% and regimen s effectiveness was 50% for susceptible bacteria). Recent studies in adults using shorter regimens of Rifampicin plus Pyrazinamide for 2 months were fraught with unexpected high rates of hepatotoxicity including fatalities from liver failure. Though reports of this regimen being well-tolerated in a small number of children are there [43], yet in view of lack of efficacy and large safety data in children, CDC has not recommended its use in the pediatric age group [44]. Indian Academy of Pediatrics (IAP) in 1997 [45] issued guidelines for chemoprophylaxis with 6 months of INH and Rifampicin (HR) for: asymptomatic Mantoux positive <3 years of age, asymptomatic Mantoux positive <5 years of age with grades III or IV malnutrition, Mantoux positive recent converter/no signs, children <3 years of age with history of positive contact, children <5 years of age with grades III or IV malnutrition with history of positive contact. According to the recent guidelines by IAP [5], 6 months of INH preventive therapy is recommended for all contacts of an infectious case under 6 years of age, irrespective of their BCG or nutritional status. PPD positive children over 6 years of age who do not have any evidence of active disease but are planned for immunosuppressive therapy (e.g., children with nephrotic syndrome, acute leukemia etc.) should also receive prophylaxis. Though the HR combination can make the duration shorter evidently but the group does not recommend it due to the risk of misuse of Rifampicin. Also, all household contacts should be screened for symptoms of the disease and INH is provided to those less than 5 years of age and to all HIV-infected children. References 1. Amberson JB. The significance of latent forms of tuberculosis. N Engl J Med. 1938;219: Pediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents. Pediatrics. 2004;114: Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities. MMWR Recomm Rep. 1994;43: Chugh S. Paediatric tuberculosis and DOTS strategy under RNTCP. J Indian Med Assoc. 2008;106: Working Group on Tuberculosis, Indian Academy Of Pediatrics (IAP). Consensus statement on childhood tuberculosis. Indian Pediatr. 2010;47: Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR. Childhood pulmonary tuberculosis: old wisdom and new challenges. Am J Respir Crit Care Med. 2006;173: Connell TG, Curtis N, Ranganathan SC, Buttery JP. Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax. 2006;61: Dogra S, Narang P, Mendiratta DK, et al. Comparison of a whole blood interferon-gamma assay with tuberculin skin testing for the detection of tuberculosis infection in hospitalized children in rural India. J Infect. 2007;54: Marais BJ, Pai M. New approaches and emerging technologies in the diagnosis of childhood tuberculosis. Paediatr Respir Rev. 2007;8: Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S Enarson DA. Use of the tuberculin skin test in children. Paediatr Respir Rev. 2004;5:S Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149: Lighter J, Rigaud M, Eduardo R, Peng CH, Pollack H. Latent tuberculosis diagnosis in children by using the QuantiFERON-TB Gold In-Tube test. Pediatrics. 2009;123: Liebeschuetz S, Bamber S, Ewer K, et al. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet. 2004;364: Detjen AK, Keil T, Roll S, et al. Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis. 2007;45: Zellweger JP. Latent tuberculosis: which test in which situation? Swiss Med Wkly. 2008;138:31 7.
5 468 Indian J Pediatr (April 2011) 78(4): Ciaschetti A, Franchi A, Richeldi L, et al. Screening of latent tuberculosis infection in health care workers by QuantiFERON-TB and tuberculin skin test. G Ital Med Lav Ergon. 2007;29: Bakir M, Millington KA, Soysal A, et al. Prognostic value of a T cellbased, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med. 2008;149: Diel R, Loddenkemper R, Meywald-Walter K, Gottschalk R, Nienhaus A. Comparative performance of tuberculin skin test, QuantiFERON-TB-Gold In Tube assay, and T-Spot.TB test in contact investigations for tuberculosis. Chest. 2009;135: Nakaoka H, Lawson L, Squire SB, et al. Risk for tuberculosis among children. Emerg Infect Dis. 2006;12: Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet. 2003;361: Hill PC, Brookes RH, Fox A, et al. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis. 2004;38: Hill PC, Brookes RH, Adetifa IM, et al. Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis. Pediatrics. 2006;117: Nicol MP, Davies MA, Wood K, et al. Comparison of T-SPOT.TB assay and tuberculin skin test for the evaluation of young children at high risk for tuberculosis in a community setting. Pediatrics. 2009;123: Pai M, O Brien R. Tuberculosis diagnostics trials: do they lack methodological rigor? Expert Rev Mol Diagn. 2006;6: Ranganathan S, Connell T, Curtis N. Interferon-gamma release assays in children no better than tuberculin skin testing? J Infect. 2007;54: Naseer A, Naqvi S, Kampmann B. Evidence for boosting Mycobacterium tuberculosis-specific IFN-gamma responses at 6 weeks following tuberculin skin testing. Eur Respir J. 2007;29: Bergamini BM, Losi M, Vaienti F, et al. Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents. Pediatrics. 2009;123: Arend SM, Franken WP, Aggerbeck H, et al. Double-blind randomized Phase I study comparing rdesat-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection. Tuberculosis. 2008;88: Nelson LJ, Jereb JA, Castro KG. New guidelines about latent tuberculosis infection in children and adolescents: a welcome advancement. Pediatrics. 2004;114: American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49: Mount FW, Ferebee SH. Preventive effects of isoniazid in the treatment of primary tuberculosis in children. N Engl J Med. 1961;265: Comstock GW, Hammes LM, Pio A. Isoniazid prophylaxis in Alaskan Boarding schools. A comparison of two doses. Am Rev Respir Dis. 1969;100: Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26: Stein MT, Liang D. Clinical hepatotoxicity of isoniazid in children. Pediatrics. 1979;64: O Brien RJ, Long MW, Cross FS, Lyle MA, Snider Jr DE. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis. Pediatrics. 1983;72: Finnell SM, Christenson JC, Downs SM. Latent tuberculosis infection in children: a call for revised treatment guidelines. Pediatrics. 2009;123: Villarino ME, Ridzon R, Weismuller PC, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med. 1997;155: Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child. 1998;78: Nakajo MM, Rao M, Steiner P. Incidence of hepatotoxicity in children receiving isoniazid chemoprophylaxis. Pediatr Infect Dis J. 1989;8: Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations Thorax. 1998;53: Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9 month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007;45: Magdorf K, Arizzi-Rusche AF, Geiter LJ, O Brien RJ, Wahn U. Compliance and tolerance of new antitubercular short-term chemopreventive regimens in childhood a pilot project. Pneumologie. 1994;48: Prevention CDC. Update: Adverse event data and Revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection United States, Indian Academy of Pediatrics. Treatment of childhood tuberculosis: Consensus Statement of IAP Working Group. Indian Pediatr. 1997;34:
Guidelines for TB Blood Testing. Minnesota Department of Health TB Prevention and Control Program June 2011
Guidelines for TB Blood Testing Minnesota Department of Health TB Prevention and Control Program June 2011 Outline Interferon-Gamma Release Assays aka TB blood tests 1. What are they? 2. What are the current
More informationWhat is an IGRA? What is an IGRA? Are they available here? How do I use them? Learning Objectives
What is an IGRA? Are they available here? How do I use them? Debbie Staley, RN, MPH TB Nurse Consultant VDH Division of Disease Prevention TB Control Program Learning Objectives Participants will be able
More informationCDC TB Testing Guidelines and Recent Literature Update
Pocket Guide QuantiFERON -TB Gold CDC TB Testing Guidelines and Recent Literature Update Using IGRAs for TB screening in your patients June 2010 A full copy of the US Centers for Disease Control and Prevention
More informationLisa Y. Armitige, MD, PhD has the following disclosures to make:
Interferon Gamma Release Assays (IGRAs) Lisa Y. Armitige, MD, PhD May 13, 2015 TB for Pulmonologist Phoenix, AZ March 13, 2015 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following
More informationMassachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention
Massachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention Screening Infants and Children for Tuberculosis in Massachusetts Executive Summary In Massachusetts,
More informationSanta Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014. Frequently Asked Questions
Frequently Asked Questions A child has history of BCG vaccination, should they have TST or IGRA? According to the American Academy of Pediatrics Red Book (2012), Interferon Gamma Release Assay (IGRA) is
More informationDRAFT FOR CONSULTATION
Interferon Gamma Release Assay (IGRA) testing for tuberculosis (TB) - Questions & Answers (Q&As) For Health Care Workers HPA Tuberculosis Programme Board DRAFT FOR CONSULTATION October 2007 Interferon
More informationHealth Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for Tuberculosis (TB)
Health Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for Tuberculosis (TB) Draft Interim HPA Guidance HPA Tuberculosis Programme Board Health Protection
More informationPediatric Latent TB Diagnosis and Treatment
Date Updated: April 2015 Guidelines Reviewed: 1. CDC Latent TB Guidelines 2. Harborview Pediatric Clinic Latent TB Management, 2010 3. Pediatric Associates Latent TB Guidelines, 2013 4. Seattle Children
More informationT tuberculin Skin Test (TST) and QFT-GIT in Military Personnel
2 COMPARISON OF MANTOUX AND QUANTIFERON-TB GOLD TEST FOR DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION IN ARMY PERSONNEL Willeke P.J. Franken 1, Joost F. Timmermans 2, Corine Prins 1, Evert-Jan H.J. Slootman
More informationPregnancy and Tuberculosis. Information for clinicians
Pregnancy and Tuberculosis Information for clinicians When to suspect Tuberculosis (TB)? Who is at risk of TB during pregnancy? Recent research suggests that new mothers are at an increased risk of TB
More informationChapter 3 Testing for Tuberculosis Infection and Disease
Chapter 3 Testing for Tuberculosis Infection and Disease Table of Contents Chapter Objectives.... 45 Introduction.... 47 Identifying High-Risk Groups for M. tuberculosis Testing... 47 Testing Methods for
More informationRole of Quantiferon-TB Gold Assays in Detecting Latent Tuberculous Infection among Contacts of Active Tuberculous Patients *
Med. J. Cairo Univ., Vol. 79, No. 1, June 169-175, 2011 www.medicaljournalofcairouniversity.com Role of Quantiferon-TB Gold Assays in Detecting Latent Tuberculous Infection among Contacts of Active Tuberculous
More informationTUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY. Stephanie N. Lin MD 2/12/2016
TUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY Stephanie N. Lin MD 2/12/2016 Epidemiology of TB 9.6 million new cases in 2014 12% of them are in HIV positive patients 1.5 million deaths in 2014 ~646
More informationManaging Contacts. Challenges... 202. General Principles... 204. Summary of Options... 205. Variables to Consider... 205. Treatment Options...
10 Managing Contacts Challenges............ 202 General Principles...... 204 Summary of Options.... 205 Variables to Consider... 205 Treatment Options...... 206 Treatment of Children... 209 Window Prophylaxis....
More informationScreening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults)
Screening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults) H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg
More informationRecent Advances in The Treatment of Mycobacterium Tuberculosis
Recent Advances in The Treatment of Mycobacterium Tuberculosis Dr Mohd Arif Mohd Zim Senior Lecturer & Respiratory Physician Faculty of Medicine, Universiti Teknologi MARA mohdarif035@salam.uitm.edu.my
More informationInterferon-gamma-release assays: Better than tuberculin skin testing?
REVIEW CME CREDIT EDUCATIONAL OBJECTIVE: Readers will use and interpret the new blood tests for tuberculosis correctly CYNDEE MIRANDA, MD Department of Infectious Disease, Medicine Institute, Cleveland
More informationATTACHMENT 2. New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS
ATTACHMENT 2 New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS 1. QUESTION Is it required to submit the Annual Report of TB Testing in Schools Form (TB-57) to the New Jersey
More informationChapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI.... 112 LTBI Treatment Regimens.... 118 LTBI
More informationPaediatrica Indonesiana. Limitations of the Indonesian Pediatric Tuberculosis Scoring System in the context of child contact investigation
Paediatrica Indonesiana VOLUME 51 November NUMBER 6 Original Article Limitations of the Indonesian Pediatric Tuberculosis Scoring System in the context of child contact investigation Rina Triasih 1,2,
More informationNevada State Health Division Technical Bulletin
Nevada State Health Division Technical Bulletin Topic: Using QuantiFERON and Tuberculin Skin Test to Screen for TB Section/Program/Contact: Bureau of Community Health / Tuberculosis Program / Susanne Paulson,
More informationTB preventive therapy in children. Introduction
TB preventive therapy in children H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg Children s Hospital Introduction Children are
More informationTuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California
Tuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California 1 of 7 Table of Contents Preface 2 TB Symptoms and TB History 2 Initial Screening 2 Follow-Up Screening
More informationLEARNING OUTCOMES. Identify children at risk of developing TB disease. Correctly manage and refer children suspected of TB. Manage child contacts
TB in Children 1a TB IN CHILDREN 2 LEARNING OUTCOMES Identify children at risk of developing TB disease Correctly manage and refer children suspected of TB Manage child contacts 3 TB Infection and Disease
More informationGUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA
GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA 2010 1 TB prophylaxis GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS Background
More informationGuidelines on targeted tuberculin testing and treatment of latent tuberculosis infection
Guidelines on targeted tuberculin testing and treatment of latent tuberculosis infection Tuberculosis and Chest Service (Last update on 31March 2015) Internal guidelines of the Tuberculosis & Chest Service
More informationTuberculosis Surveillance and Screening for Long Term Care Facilities in Colorado
Tuberculosis Surveillance and Screening for Long Term Care Facilities in Colorado Developed by the Colorado Medical Directors Association and The Colorado Department of Public Health and Environment Introduction:
More informationTable. Positive Purified Protein Derivative Results (Pediatrics In Review Apr 2008)
PPD and TB Sreening COMPETENCY- The resident should know the risk factors for TB exposure, when to screen, and the appropriate criteria for recognizing a positive PPD in children of different age groups
More informationTuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges
Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges John B. Kaneene, DVM, MPH, PhD University Distinguished Professor of Epidemiology Director, Center for Comparative Epidemiology
More informationUpdated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection United States, 2010
Morbidity and Mortality Weekly Report www.cdc.gov/mmwr Recommendations and Reports June 25, 2010 / Vol. 59 / No. RR-5 Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium
More informationPerils and Pitfalls in Clinical Trials of Diagnostic Tests for Tuberculosis. Richard O Brien, MD Foundation for Innovative New Diagnostics Geneva
Perils and Pitfalls in Clinical Trials of Diagnostic Tests for Tuberculosis Richard O Brien, MD Foundation for Innovative New Diagnostics Geneva 1 Outline of Presentation Statement of the problem Common
More informationAssessing patients for infection with Mycobacterium tuberculosis
ORIGINAL STUDIES The Likelihood of an Indeterminate Test Result from a Whole-Blood Interferon- Release Assay for the Diagnosis of Mycobacterium tuberculosis Infection in Children Correlates With Age and
More informationTuberculosis. Subject. Goal/Objective. Instructions. Rationale. Operations Directorate, Health Branch Immigration Medical Examination Instructions
Subject Instructions for the screening of clients to detect tuberculosis (TB) in the context of the Canadian immigration medical examination (IME). Goal/Objective These instructions are provided to ensure
More informationTuberculosis: FAQs. What is the difference between latent TB infection and TB disease?
Tuberculosis: FAQs What is TB disease? Tuberculosis (TB) is a disease caused by bacteria (germs) that are spread from person to person through the air. TB usually affects the lungs, but it can also affect
More informationChallenges in Pediatric Tuberculosis. Mimi Emig, MD Spectrum Health Kent County Health Department
Challenges in Pediatric Tuberculosis Mimi Emig, MD Spectrum Health Kent County Health Department Pediatric Tuberculosis: A Missed Public Health Opportunity Mimi Emig, MD Spectrum Health Kent County Health
More informationTuberculosis in Children and Adolescents
Tuberculosis in Children and Adolescents Ritu Banerjee, MD, Ph.D TB Clinical Intensive April 8, 2015 2014 MFMER slide-1 Disclosures None 2014 MFMER slide-2 Objectives Describe the epidemiology of pediatric
More informationTB Prevention, Diagnosis and Treatment. Accelerating advocacy on TB/HIV 15th July, Vienna
TB Prevention, Diagnosis and Treatment Accelerating advocacy on TB/HIV 15th July, Vienna Diagnosis Microscopy of specially stained sputum is the main test for diagnosing TB (1 2 days) TB bacilli seen in
More informationTargeted Testing and Treatment of Latent Tuberculosis Infection in Adults and Children
C D H S / C T C A J O I N T G U I D E L I N E S Targeted Testing and Treatment of Latent Tuberculosis Infection in Adults and Children Targeted Skin Testing and Treatment of Latent Tuberculosis Infection
More informationChildhood Tuberculosis Some Basic Issues. Jeffrey R. Starke, M.D. Baylor College of Medicine
Childhood Tuberculosis Some Basic Issues Jeffrey R. Starke, M.D. Baylor College of Medicine TUBERCULOSIS IS A SOCIAL DISEASE WITH MEDICAL IMPLICATIONS THE GREAT PARADOX OF TUBERCULOSIS A CAUTIONARY TALE
More informationFrequently Asked Questions
Frequently Asked Questions QuantiFERON -TB Gold Health Professionals www.quantiferon.com 2 FAQ - Health Professionals Table of contents About TB 6 What is latent TB? And how is it different from active
More informationClinical description 2 Laboratory test for diagnosis 3. Incubation period 4 Mode of transmission 4 Period of communicability 4
Tuberculosis Contents Epidemiology in New Zealand 2 Case definition 2 Clinical description 2 Laboratory test for diagnosis 3 Case classification 3 Spread of infection 4 Incubation period 4 Mode of transmission
More informationFor reprint orders, please contact reprints@future-drugs.com. Diagnosis of latent. Expert Rev. Anti Infect. Ther. 3(6), 981 993 (2005)
Review For reprint orders, please contact reprints@future-drugs.com Diagnosis of latent Mycobacterium tuberculosis infection: is the demise of the Mantoux test imminent? James S Rothel and Peter Andersen
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Treatment of Latent Tuberculosis Infection and Tube rc ulos is Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National
More informationTuberculosis in children in Europe -the ptbnet
Tuberculosis in children in Europe -the ptbnet Beate Kampmann FRCPCH PhD A/Professor in Paediatric Infection & Immunity Consultant Paediatrician Imperial College London, UK and Institute of Infectious
More informationManagement of a child failing first line TB treatment.
Management of a child failing first line TB treatment. Robert Gie Desmond Tutu Tuberculosis Centre Department of Paediatric and Child Health Stellenbosch University South Africa. Tygerberg Hospital Complex
More informationJournal of Infectious Diseases Advance Access published January 26, 2015
Journal of Infectious Diseases Advance Access published January 26, 2015 1 Effect of immune status on serial QuantiFERON-TB Gold In-Tube LTBI screening in persons with HIV in a low TB incidence country
More informationSerial Testing for TB Infection with IGRAs: Understanding the Sources of Variability
Serial Testing for TB Infection with IGRAs: Understanding the Sources of Variability Niaz Banaei MD Assistant Professor of Pathology and Medicine Director, Fellowship in Global Health Diagnostics Director,
More informationX-Plain Pediatric Tuberculosis Reference Summary
X-Plain Pediatric Tuberculosis Reference Summary Introduction Tuberculosis, or TB, is a bacterial infection that causes more deaths in the world than any other infectious disease. When a child gets TB,
More informationInterferon-gamma Release Assays: the Good, the Bad, and the Ugly
Interferon-gamma Release Assays: the Good, the Bad, and the Ugly Susan E. Dorman, MD Center for TB Research Johns Hopkins University School of Medicine Maryland Center for Tuberculosis Control and Prevention
More informationSan Francisco Treatment Guidelines for Latent Tuberculosis Infection
City and County of San Francisco Department of Public Health Tuberculosis Control Unit Julie Higashi, MD, PhD Director Population Health Division Edwin M. Lee Mayor Disease Prevention and Control Branch
More informationMAJOR ARTICLE. Treatment of Latent Tuberculosis CID 2007:45 (15 September) 715
MAJOR ARTICLE The Effectiveness of a 9-Month Regimen of Isoniazid Alone versus 3- and 4-Month Regimens of Isoniazid plus Rifampin for Treatment of Latent Tuberculosis Infection in Children: Results of
More informationGuidelines for Tuberculosis Control in New Zealand 2010 Chapter 8: Diagnosis and Treatment of Latent Tuberculosis Infection
Guidelines for Tuberculosis Control in New Zealand 2010 Chapter 8: Diagnosis and Treatment of Latent Tuberculosis Infection Ministry of Health. 2010. Guidelines for Tuberculosis Control in New Zealand
More informationLatent Tuberculosis Infection: A Guide for Primary Health Care Providers
Latent Tuberculosis Infection: A Guide for Primary Health Care Providers A B Latent Tuberculosis Infection: A Guide for Primary Health Care Providers U.S. Department of Health and Human Services Centers
More informationChapter 1 Overview of Tuberculosis Epidemiology in the United States
Chapter 1 Overview of Tuberculosis Epidemiology in the United States Table of Contents Chapter Objectives.... 1 Progress Toward TB Elimination in the United States.... 3 TB Disease Trends in the United
More informationRole of QuantiFERON-TB Test in Detection of Children Infected with Mycobacterium tuberculosis
ORIGINAL ARTICLE Tanaffos (2010) 9(3), 22-27 2010 NRITLD, National Research Institute of Tuberculosis and Lung Disease, Iran Role of QuantiFERON-TB Test in Detection of Children Infected with Mycobacterium
More informationA Three-Way Comparison of Tuberculin Skin Testing, QuantiFERON-TB Gold and T-SPOT.TB in Children
A Three-Way Comparison of Tuberculin Skin Testing, QuantiFERON-TB Gold and T-SPOT.TB in Children Tom G. Connell 1,2,3., Nicole Ritz 1,2,3., Georgia A. Paxton 4, Jim P. Buttery 1,2,3, Nigel Curtis 1,2,3
More informationNew York City Department of Health Protocols for Latent TB Infection Treatment
New York City Department of Health Protocols for Latent TB Infection Treatment CONTENT A. Medical evaluation for latent TB infection (LTBI) treatment 1. Medical history and physical examination 2. Chest
More informationInterferon Gamma Release Assays (IGRAs) in the Diagnosis of Tuberculosis
Interferon Gamma Release Assays (IGRAs) in the Diagnosis of Tuberculosis Richard B. Clark, PhD, D(ABMM) Quest Diagnostics Nichols Institute Chantilly, VA Dale Schwab, PhD, D(ABMM) Quest Diagnostics Nichols
More informationPolicy Directive: compliance is mandatory
Policy Directive: compliance is mandatory Policy for Control of Tuberculosis in South Australian Health Services Policy developed by: Public Health and Clinical Coordination Approved at Portfolio Executive
More informationSan Francisco Guidelines on the Use of QuantiFERON-TB Gold (In Tube Method) for the Diagnosis of Latent TB Infection
San Francisco Guidelines on the Use of QuantiFERON-TB Gold (In Tube Method) for the Diagnosis of Latent TB Infection Rationale When to Screen for TB Choosing the Right TB Test Patient Registration Pre-Test
More informationAn Evaluation of QuantiFERON-TB Gold In-Tube and Immunological Tests for TB Diagnosis in Iraqi Patients
An Evaluation of QuantiFERON-TB Gold In-Tube and Immunological Tests for TB Diagnosis in Iraqi Patients Mohemid M. Al-Jebouri 1 and Nuha M. Wahid 2 1 Department of Microbiology, College of Medicine, University
More informationContact centred strategies to reduce transmission of M. leprae
Contact centred strategies to reduce transmission of M. leprae Jan Hendrik Richardus, MD, PhD Department of Public Health Erasmus MC, University Medical Center Rotterdam The Netherlands Outline lecture
More informationSPECIAL FEATURES: HEALTH POLICY
Public Health Nursing 0737-1209/ 2013 Wiley Periodicals, Inc. doi: 10.1111/phn.12083 SPECIAL FEATURES: HEALTH POLICY Cost-effectiveness of Using Quantiferon Gold (QFT-G) versus Tuberculin Skin Test (TST)
More informationMaria Dalbey RN. BSN, MA, MBA March 17 th, 2015
Maria Dalbey RN. BSN, MA, MBA March 17 th, 2015 2 Objectives Participants will be able to : Understand the Pathogenesis of Tuberculosis (TB) Identify the Goals of Public Health for TB Identify Hierarchy
More information2011 NTP Paediatric guidelines update- final draft
Childhood TB Investigation and management of children suspected to have tuberculosis (TB) or who are close contacts of a TB case (sputum smear positive or negative) Key facts Children who are close contacts
More informationTuberculosis Exposure Control Plan for Low Risk Dental Offices
Tuberculosis Exposure Control Plan for Low Risk Dental Offices A. BACKGROUND According to the CDC, approximately one-third of the world s population, almost two billion people, are infected with tuberculosis.
More informationRevised National Tuberculosis Control Programme (RNTCP) Dr. NAVPREET
Revised National Tuberculosis Control Programme (RNTCP) Dr. NAVPREET Assistant Prof., Deptt. of Community Medicine GMCH Chandigarh Problem Statement of TB in India India accounts for nearly 1/4 th of global
More informationTuberculousmeningitis: what is the best treatment regimen?
Tuberculousmeningitis: what is the best treatment regimen? H S Schaaf Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University
More informationHow To Test For Latent Tuberculosis
IGRAs: What do they tell and what don t they tell us? 2 nd European Advanced Clinical Tuberculosis Course Monday 22 nd September 2014 Amsterdam, Netherlands Ibrahim Abubakar Professor of Infectious Disease
More informationT()LED() Name ofpolicy: Mandatory Tuberculosis (TB) Screening of Students from World Health Organization Designated High TB Prevalence Countries
Name ofpolicy: Mandatory Tuberculosis (TB) Screening of Students from World Health Organization Designated High TB Prevalence Countries Policy Number: 3364-81-04-030 T()LED() Revision date: I 0/22/13 Approving
More informationDiagnosis of Tuberculosis Infection
Diagnosis of Tuberculosis Infection CONTENTS Introduction... 7.2 Purpose... 7.2 Policy... 7.2 High-Risk Groups... 7.3 Diagnosis of Tuberculosis Infection... 7.4 Interferon gamma release assays... 7.4 Mantoux
More informationTuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University
Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die
More informationALTERNATIVES TO THE TUBERCULIN SKIN TEST: INTERFERON-γ ASSAYS IN THE DIAGNOSIS OF MYCOBACTERIUM TUBERCULOSIS INFECTION
Indian Journal of Medical Microbiology, (2005) 23 (3):151-158 Review Article ALTERNATIVES TO THE TUBERCULIN SKIN TEST: INTERFERON-γ ASSAYS IN THE DIAGNOSIS OF MYCOBACTERIUM TUBERCULOSIS INFECTION M Pai
More informationGuideline. Treatment of tuberculosis in pregnant women and newborn infants. Version 3.0
Guideline Treatment of tuberculosis in pregnant women and newborn infants Version 3.0 Key critical points The decision to treat tuberculosis (TB) in pregnancy must consider the potential risks to mother
More informationNurse Aide Training Program Application Checklist
Nurse Aide Training Program Application Checklist The following checklist must be completed before enrolling in the Nurse Aide Training course: Complete, sign, and date the Application Form Have the physical
More informationECDC GUIDANCE. Management of contacts of MDR TB and XDR TB patients. www.ecdc.europa.eu
Management of contacts of MDR TB and XDR TB patients www.ecdc.europa.eu Management of contacts of MDR TB and XDR TB patients The content of this guidance was developed by the European Centre for Disease
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 TB in the HIV Patient Lisa Armitige, MD, PhD November 13, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests
More information3. Blood and blood products such as serum, plasma, and other blood components.
Mississippi Downloaded 01/2011 101.11 Infectious Medical Waste. The term "infectious medical waste" includes solid or liquid wastes which may contain pathogens with sufficient virulence and quantity such
More informationTreatment of TB a pharmacy perspective
Treatment of TB a pharmacy perspective Colm McDonald, Antimicrobial Stewardship Pharmacist (Acting) National TB Conference, St. James s Hospital 6 th May 2011 Overview of presentation Role of the pharmacist
More informationRecognised as a world leader and a prominent clinical researcher in South Africa
Expert Talks Prof. Peter Donald Emeritus professor in Pediatrics and Child Health at the Faculty of Health Sciences of the University of Stellenbosch and Tygerberg Children's Hospital, South frica n internationally
More informationRisk for Tuberculosis in Swiss Hospitals. Content. Introduction. Dr. med. Alexander Turk Zürcher Höhenklinik Wald alexander.turk@zhw.
Risk for Tuberculosis in Swiss Hospitals 17. Tuberkulose Symposium Münchenwiler Risk for Tuberculosis in Swiss Hospitals Dr. med. Alexander Turk Zürcher Höhenklinik Wald alexander.turk@zhw.ch 1 Content
More informationAmerican College Health Association (ACHA) TB Screening and Targeted Testing Recommendations Gregory Juckett, MD, MPH Professor of Family Medicine
American College Health Association (ACHA) TB Screening and Targeted Testing Recommendations Gregory Juckett, MD, MPH Professor of Family Medicine West Virginia University gjuckett@hsc.wvu.edu Objectives
More informationSerial Testing of Refugees for Latent Tuberculosis Using the QuantiFERON-Gold In-Tube: Effects of an Antecedent Tuberculin Skin Test
Am. J. Trop. Med. Hyg., 80(4), 2009, pp. 628 633 Copyright 2009 by The American Society of Tropical Medicine and Hygiene Serial Testing of Refugees for Latent Tuberculosis Using the QuantiFERON-Gold In-Tube:
More informationTUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG
TUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG Tx CENTERS Tuberculosis Control Program Health and Human Services Agency San Diego County INTRODUCTION Reducing TB disease requires
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Tuberculosis Revised August 2015 Tuberculosis 1.0 Provincial Reporting Confirmed and suspect cases
More informationTITLE: Infection Control Plans TB, HIV, Biohazard Waste Management and Decontamination of Medical and Dental Equipment CD-176000
CD-176000 Courage Responsibility Ethics Dedication - CREDibly serving the public safety of New Mexico ISSUE DATE: 04/14/90 REVIEW/REVISED: 02/16/15 EFFECTIVE DATE: 04/14/90 TITLE: Infection Control Plans
More informationRegulations for Tuberculosis Control in Minnesota Health Care Settings
Regulations for Tuberculosis Control in Minnesota Health Care Settings A guide for implementing tuberculosis (TB) infection control regulations in your facility Tuberculosis Prevention and Control Program
More informationTuberculosis OUR MISSION THE OPPORTUNITY
Tuberculosis OUR MISSION Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. Our Global Health Program is
More informationTargeted Testing for Tuberculosis Infection
Targeted Testing for Tuberculosis Infection CONTENTS Introduction... 3.2 Purpose... 3.2 Policy... 3.2 When to Conduct Targeted Testing... 3.3 Approaches to increasing targeted testing and treatment for
More informationMANAGEMENT OF TUBERCULOSIS
MANAGEMENT OF TUBERCULOSIS Dean B. Ellithorpe, M.D. Clinical Professor of Medicine Section of Pulmonary Diseases, Critical Care and Environmental Medicine Tulane University School of Medicine INTRODUCTION
More informationAssisted Living - TB Risk Assessment
Montana DPHHS Tuberculosis Program Assisted Living - TB Risk Assessment Assisted Living, Adult Day Care, Adult Foster Care & Transitional Living Centers Today s Date Facility Address Phone County Completed
More informationCTCA POSITION ON TB EXAMINATION OF SCHOOL EMPLOYEES AND VOLUNTEERS
CTCA POSITION ON TB EXAMINATION OF SCHOOL EMPLOYEES AND VOLUNTEERS Introduction Although progress has been made, tuberculosis (TB) continues to be a significant public health problem; appropriate TB examination
More informationU.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention National Center for HIV, STD, and TB Prevention Division of Tuberculosis Elimination Public
More informationEpidémiologie et maîtrise de la tuberculose: situation internationale
Epidémiologie et maîtrise de la tuberculose: situation internationale Paris, 24 mars 2009 Hans L Rieder Union Internationale Contre la Tuberculose et les Maladies Respiratoires Relationship between estimated
More informationHawaii Administrative Rules. Title 11. Department of Health. Chapter 164. Tuberculosis
Hawaii Administrative Rules Title 11 Department of Health Chapter 164 Tuberculosis 11-164-1 Purpose 11-164-2 Definitions 11-164-3 Reports to the department 11-164-4 Content of report 11-164-5 Examination
More informationNo influence of haemodialysis on interferon production in the QuantiFERON-TB Gold-In-Tube test
ORIGINAL ARTICLE JN EPHROL 24( 2011; 05) : 625-630 DOI:10.5301/JN.2011.6325 No influence of haemodialysis on interferon production in the QuantiFERON-TB Gold-In-Tube test Martine Hoogewerf 1, Greet J.
More informationQuantiFERON TB Gold In Tube Method (QGIT Test) Manufacturer: Cellestis Inc. (USA) a QIAGEN Company
QuantiFERON TB Gold In Tube Method (QGIT Test) Manufacturer: Cellestis Inc. (USA) a QIAGEN Company P1078 TB APPRISE TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed
More informationChapter 6 Treatment of Tuberculosis Disease
Chapter 6 Treatment of Tuberculosis Disease Table of Contents Chapter Objectives.... 139 Introduction.... 141 Treatment and Monitoring Plan.... 143 Adherence Strategies... 143 TB Disease Treatment Regimens....
More informationUniversity of Bergen
University of Bergen Comparison of Tuberculin Skin Test and QuantiFERON TB Gold In-tube Assay for the diagnosis of tuberculosis infection and disease in young children; study conducted as part of the development
More information